once monthly glp 1 agonist ADA 2026 confirmed what many of us have been anticipating for years. We're entering a new era of obesity medicine: triple agonists, oral GLP-1s, injections, and therapies targeting obesity, diabetes, and GLP-1 Agonists - What is

This new trial built on a previous one published in NEJM last fall (I previously reviewed here) for the same indication, but the only difference was the inclusion of people with diabetes

These cardiovascular benefits have influenced treatment algorithms, with guidelines recommending GLP-1 receptor agonists with proven cardiovascular benefit for patients with type 2 diabetes and atherosclerotic cardiovascular disease

3 A twin study further supports a strong genetic contribution, showing higher concordance in monozygotic than in dizygotic twins

[DOI] [PMC free article] [PubMed] [Google Scholar] 56.Schmidt H.D., Mietlicki-Baase E.G., Ige K.Y., Maurer J.J., Reiner D.J., Zimmer D.J., Van Nest D.S., Guercio L.A., Wimmer M.E., Olivos D.R., et al

To date, Ro has helped over 2 million people understand their benefits coverage to get the best medication for them